MGO One Seven LLC Buys 14,699 Shares of DexCom, Inc. $DXCM

MGO One Seven LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 358.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,799 shares of the medical device company’s stock after acquiring an additional 14,699 shares during the quarter. MGO One Seven LLC’s holdings in DexCom were worth $1,265,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Brighton Jones LLC raised its holdings in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC grew its position in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the last quarter. Empowered Funds LLC grew its position in shares of DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the last quarter. Focus Partners Wealth raised its stake in shares of DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after acquiring an additional 841 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its position in DexCom by 23.9% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,125 shares of the medical device company’s stock valued at $98,000 after acquiring an additional 217 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $69.24 on Friday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The company has a market cap of $27.00 billion, a PE ratio of 38.47, a price-to-earnings-growth ratio of 1.26 and a beta of 1.48. The company’s 50 day moving average is $64.74 and its 200 day moving average is $71.76.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.45 EPS. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. BTIG Research cut their price target on shares of DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Evercore ISI assumed coverage on DexCom in a research note on Tuesday, November 25th. They set an “in-line” rating and a $68.00 target price on the stock. Piper Sandler set a $75.00 target price on DexCom and gave the company a “buy” rating in a research report on Friday, October 31st. The Goldman Sachs Group lowered their price target on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Finally, Citigroup restated a “buy” rating and set a $77.00 price target (up previously from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.30.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares of the company’s stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This represents a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,866 shares of company stock worth $448,177 over the last quarter. 0.32% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.